Everything below concerns lyophilized powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off white powder | Typical lyophilized form |
| Water solubility | Soluble | May need a small organic co-solvent |
| Purity assessment | Chromatographic peak area | Most certificates report a percentage figure |
| Storage temperature | Minus 20 C or lower | Dry, dark, sealed container |
| Identity check | Electrospray mass spectrometry | Compared against theoretical mass |
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
== Pathophysiology == The pathophysiology of unstable angina is controversial. Previously, unstable angina was assumed to be angina pectoris caused by disruption of an atherosclerotic plaque with partial thrombosis and possibly embolization or vasospasm leading to myocardial ischemia. However, sensitive troponin assays reveal rise of cardiac troponin in the bloodstream with episodes of even mild myocardial ischemia. Since unstable angina is assumed to occur in the setting of acute myocardial ischemia without troponin release, the concept of unstable angina is being questioned with some calling for retiring the term altogether.
== Responses to foods == Big gastrin is one form of gastrin predominate in circulation after a meal, another major form is called little gastrin (G17). Both forms of gastrin have been isolated from human gastrinoma and hog antral mucosa. G34 is carboxy-amidated and can be sulphated or unsulphated at the tyrosine residues. Binding of gastrin to the receptors in stomach can cause the secretion of hydrochloric acids (HCl), the gastric acid. Duodenal ulcer patients tend to have higher than normal basal and maximal rate of gastric acid secretion, while gastric ulcer patients have lower than normal basal and maximal of gastric acid output. Comparing G34 in normal and peptic ulcer subjects by using radioimmunoassay in fasting serum and after feeding, basal G34 was found similar in normal and duodenal ulcer but raised in gastric ulcer before meal. After a meal, the concentration of G34 was increased in both duodenal ulcer patients and gastric ulcer patients, which significantly higher than normal people.
Signs and symptoms of methemoglobinemia (methemoglobin level above 10%) include shortness of breath, cyanosis, mental status changes (~50%), headache, fatigue, exercise intolerance, dizziness, and loss of consciousness. People with severe methemoglobinemia (methemoglobin level above 50%) may exhibit seizures, coma, and death (level above 70%). Healthy people may not have many symptoms with methemoglobin levels below 15%. However, people with co-morbidities such as anemia, cardiovascular disease, lung disease, sepsis, or who have abnormal hemoglobin species (e.g. carboxyhemoglobin, sulfhemoglobinemia or sickle hemoglobin) may experience moderate to severe symptoms at much lower levels (as low as 5–8%).
On the other hand, other than the lightest nuclides, nuclides with an odd number of protons and an odd number of neutrons (odd Z, odd N) are usually short-lived (a notable exception is neptunium-236 with a half-life of 154,000 years) because they readily decay by beta-particle emission to their isobars with an even number of protons and an even number of neutrons (even Z, even N) becoming much more stable. The physical basis for this phenomenon also comes from the pairing effect in nuclear binding energy, but this time from both proton–proton and neutron–neutron pairing. The relatively short half-life of such odd-odd heavy isotopes means that they are not available in quantity and are highly radioactive. According to the fissility rule proposed by Yigal Ronen, for a heavy element with Z between 90 and 100, an isotope is fissile if and only if 2 × Z − N ∈ {41, 43, 45} (where N = number of neutrons and Z = number of protons), with a few exceptions. This rule holds for all but fourteen nuclides – seven that satisfy the criterion but are nonfissile, and seven that are fissile but do not satisfy the criterion.
When a crystalline aqueous suspension of steroid is administered via intramuscular injection, a crystalline depot suspended in fluid is formed locally within the muscle. These crystals slowly dissolve and the steroid is gradually absorbed into the body, resulting in the long durations of such preparations. Particle sizes of 10 μm or less have no apparent depot effect. A larger needle size is needed for aqueous suspensions of steroids to allow the steroid crystals to pass through the needle lumen. Aqueous suspensions pose a risk of injection site reactions such as local irritation, swelling, and redness, with often severe pain. The reactions are worse with larger crystal sizes. Particle sizes of more than 300 μm in the case of estradiol benzoate have been found to be too painful for use. The local injection site reactions, which do not occur with oil solutions, have limited the clinical use of aqueous suspensions of estradiol and its esters as well as other steroids.
Sources: en.wikipedia.org
Because of the double-stranded nature of DNA, essentially all of the nucleotides take the form of Watson–Crick base pairs between nucleotides on the two complementary strands of the double helix. In contrast, both RNA and proteins are normally single-stranded. Therefore, they are not constrained by the regular geometry of the DNA double helix, and so fold into complex three-dimensional shapes dependent on their sequence. These different shapes are responsible for many of the common properties of RNA and proteins, including the formation of specific binding pockets, and the ability to catalyse biochemical reactions.
RNa + M2+ ⇌ RM+ + Na+ The water coming out of the column is relatively rich in sodium ions and poor in calcium and magnesium which are retained on the column. The column is regenerated by passing a strong solution of sodium chloride through it, so that the resin–sodium complex is again formed on the column. Ion-exchange chromatography utilizes a resin such as chelex 100 in which iminodiacetate residues, attached to a polymer backbone, form chelate complexes of differing strengths with different metal ions, allowing the ions such as Cu2+ and Ni2+ to be separated chromatographically. Another example of complex formation is in chiral chromatography in which is used to separate enantiomers from each other. The stationary phase is itself chiral and forms complexes selectively with the enantiomers. In other types of chromatography with a solid stationary phase, such as thin-layer chromatography the analyte is selectively adsorbed onto the solid. In gas–liquid chromatography (GLC) the stationary phase is a liquid such as polydimethylsiloxane, coated on a glass tube. Separation is achieved because the various components in the gas have different solubility in the stationary phase. GLC can be used to separate literally hundreds of components in a gas mixture such as cigarette smoke or essential oils, such as lavender oil.
== Research == As of 2025, the department has 162 researchers, including 110 post-graduate researchers, 50 postdoctoral researchers and 49 research groups. Research spans four divisions including cellular and molecular pathology, immunology, microbiology and parasitology and virology.
== Co-Workers == Klaus Mosbach supervised more than sixty Ph.D.’s over the years. A number of highly recognized scientists emerged from this pool, including the following professors C. Borrebaeck (in part), B.Sellergren (who is now a professor in Germany). P. Brodelius, Leif Bulow, B. Danielsson, B. Hahn-Hägerdahl (in part), A.C. Koch. Schmidt, P.O. Larsson, C. F. Mandenius, B. Mattiasson, M.O. Månsson, I.A. Nicholls (starting as post doc), R. Ohlsson (in part), Lei Ye and S. Olsson working all in Sweden. To this a number of Professors working in other countries outside Sweden including, L.Fischer, K. Haupt, C.Lowe, H.Zhang, Deepak Chandrasekaran. Mosbach collaborated with numerous companies over the years, including Biogen and later Hybritech, Eli Lilly, Igen, Hofman la Roche and was involved in the formation of start-up companies by himself likewise former students of him have been successful in starting up companies like B.Ekberg, N.Siegbahn, Kurt Nilsson, Kjell Nilsson, Dariao Kriz.
Nobody's done that before." In February 2012, the Smithsonian National Museum of American History announced that Ayyadurai had donated "a trove of documents and code" related to EMAIL. Initially, the museum—inaccurately—cited the program as one of the first to include the now common "subject and body fields, inboxes, outboxes, cc, bcc, attachments, and others. He based these elements directly off of the interoffice mail memos the doctors had been using for years, in hopes of convincing people to actually use the newfangled technology." Ayyadurai's claims drew editorial clarifications and corrections, as well as criticism from industry observers. In a followup to its acquisition announcement, the Smithsonian stated that it was not claiming that Ayyadurai had invented email, but rather that the materials were historically notable for other reasons related to trends in computer education and the role of computers in medicine. The Smithsonian statement distinguished Ayyadurai's achievement by noting that historians in the field, "have largely focused on the use of large networked computers, especially those linked to the ARPANET in the early 1970s". The statement observed that Ayyadurai's approach instead "focused on communications between linked computer terminals in an ordinary office situation".
Sources: en.wikipedia.org
The mass difference from the linker is large enough for routine detection by mass spectrometry. The unconjugated form gives a single sharp signal at its expected weight. Material that has already reacted with albumin shows a much higher mass and a broadened chromatographic peak.
Yes. Degradation proceeds faster once the powder is dissolved, especially at room temperature or after multiple freeze and thaw cycles. Working solutions are often aliquoted to avoid repeated handling. Lyophilized powder held cold and dry retains its properties far longer.
Truncated sequences, oxidized residues and aggregated forms can all elute near the main peak. Reversed phase chromatography resolves many of these species, so the number of peaks is a useful indicator of synthesis quality. A single peak does not by itself prove correct sequence, which is why mass confirmation is paired with it.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.